SEER Inquiry System - Question 20120056 Details

System Guide

Back to Search Results

SEER Inquiry System - Report

Produced: 07/31/2025 6:45 PM

Question 20120056

Export CSV Export PDF Print

Add to Report

Inquiry Details

References:

#1: SEER*Rx

#2: 2012 SEER Manual

Question:

First course treatment--Corpus Uteri: Should Arimidex be coded as hormone therapy for an endometrioid adenocarcinoma? See Discussion.

Discussion:

Per the SEER Manual, endometrial cancers may be treated with progesterone which is coded as hormone therapy for these primaries. As endometrioid adenocarcinomas are hormonally-dependent carcinomas, should an aromatase inhibitor or anti-estrogen agent also be coded as hormone therapy?

Answer:

Arimidex has not been approved to treat endometrial cancer. It is not prescribed for pre-menopausal women. Clarify with the physician why the drug was being used. If the physician states Arimidex was given to reduce tumor burden, code as hormone therapy.

See the SEER*Rx interactive database, http://seer.cancer.gov/seertools/seerrx/

Cancer Site Category:

Corpus uteri

Data Item Category:

First course treatment

Other Category:

N/A

Year:

2012